Lexeo Therapeutics, a gene therapy startup, is gearing up for an initial public offering (IPO) aiming to raise $113 million in capital. The company, which focuses on cardiac and Alzheimer’s disease gene therapies, plans to go public on Nasdaq under the symbol...
Pictured: FDA headquarters/iStock, Grandbrothers In recent years, the FDA has granted approval to some novel drugs despite failed clinical trials or minimal evidence. Guidance issued in rare or uniformly fatal diseases like amyotrophic lateral sclerosis and the...
Tauopathy, characterized by protein tau and Aβ oligomer accumulation, is a significant aspect of Alzheimer’s disease. The causal relationship between these accumulations and neurodegeneration remains unclear despite their links to various cognitive and movement...
Roche’s most advanced attempts to treat both diseases have struggled in the clinic. (iStock / Getty Images Plus) When Roche’s gantenerumab failed a pair of phase 3 studies last year, the pharma giant said it would look for “external collaborations and...
Treatment with SLS-005 demonstrated a 46% reduction in tau protein and an 18% reduction in NfL biomarker from baseline values within six months Seelos has been selected to present these data at Neuroscience 2023 to be held on November 11-15, 2023 in Washington, D.C....
